Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

SCLC, Extensive Stage × fluzoparib × 1 year × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Sarcoma, Ewing 1 SCLC, Extensive Stage 1 Fludzoparib" and Anti-angiogenic 1 Breast Neoplasms 1 Advanced Solid Tumors 1 Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

toripalimab 1 fluzoparib 1 atezolizumab 1 Topotecan 1 Temozolomide 1 PM 01183 1 Etoposide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07141771 2025-08-26

An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Not yet recruiting

SCLC, Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon ⚡